FDA approved first oral treatment for moderately to severely active Crohnﾒs disease
On May 18, 2023, the U.S. FDA approved approved Rinvoq (upadacitinib) for adults with moderately to severely active Crohnﾒs disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Rinvoq is the first approved oral product available to treat moderately to severely active Crohnﾒs disease.
Tags:
Source: U.S. Food and Drug Administration
Credit:
